Key Clinical Topics in Cardiology Sanjay Sharma, Aneil Malhotra
INDEX
Note: Page numbers in bold or italic refer to tables or figures, respectively.
A
Abciximab 15
Abdominal aortic aneurysm (AAA)
angiotensin-converting enzyme inhibitors 63
beta-blockers 63
familial incidence 63
genetic factors 63
imaging modalities 63
risk factors 63
rupture risk 63
surgical aortic repair 63
ABO blood screening 232
ACE inhibitors 208
ACS see Acute coronary syndrome (ACS)
Activated clotting time (ACT) 164
Acute coronary syndrome (ACS) 1
antiplatelet therapy for 15
management of cardiac arrests 3
symptoms 2
Acute coronary syndromes (ACS) 153
Acute fulminant myocarditis 152
Acute left ventricular failure
acute pulmonary oedema in 90
anticoagulants 92
cardiac output in 90
causes 90
chest X-ray 90
classification 91
congestion, indicators of 91
digoxin therapy 92
diuretics 91
echocardiography 9091
electrocardiogram 90
electrolyte abnormalities 92
emergency management 91
furosemide therapy 91
heart sounds 90
hypoperfusion, indicators of 91
inotropic agents 91
jugular venous pressure (JVP) 90
laboratory tests 90
nitrates therapy 91
pleural effusions 90
risk of stroke and thromboembolism 92
symptoms 90
troponin levels 90
vital signs measurements 91
Adenosine 126
Adenosine diphosphate (ADP) 15
Adenosine triphosphate (ATP) 15
AF see Atrial fibrillation (AF)
Agitated saline-based echocardigraphy 124
Agranulocytosis 9
Alcohol septal ablation (ASA) 46
Allen's test 69
Ambrisentan 110
Ambulatory ECG 45
American Heart Association 179
American Society of Anesthesiologists (ASA) 171, 172
Aminorex 108
Amiodarone 1011
Andaxanet alpha 14
Angina
anti-anginal medications 6, 7
aspirin therapy 6
beta-blockers 6
calcium channel blockers 6
Canadian Cardiovascular Society grading 5
causes 5
computed tomography coronary angiography 5
coronary artery bypass grafting 7
detecting coronary artery calcium 56
diagnosis 46
ECG stress test for 5
gold standard of diagnosis 56
incidence, age and sex differences 4
left ventricular hypertrophy in 5
lifestyle changes recommended 6
percutaneous coronary intervention 7
prevalence 4
revascularisation therapy 67
risk factors 4
short-acting nitrates 6
uncomplicated 4
Angiography see also Cardiac catheterisation
angiographic appearance of coronary arteries 33
complications of diagnostic 32
Angiosarcomas 239 see also Cardiac tumours
Angiotensin-converting enzyme (ACE) inhibitors 173
for abdominal aortic aneurysm 63
for dilated cardiomyopathy 41
for heart failure 83, 89
for restrictive cardiomyopathy 57
for type 1 diabetes mellitus 71
for type 2 diabetes mellitus 71
Angiotensin receptor blockers (ARB) 173
Antiarrhythmic drugs
aim of 8
classes 911
fast sodium channels, opening of 8
potassium channels, opening of 8
side effects 911
Anticoagulants 45, 155
as prophylactic treatment 12
clinical features for anticoagulation 12
international normalised ratio (INR) measurements of 12
novel oral anticoagulants (NOACs) 13
short-term 1213
side effects 1314
therapeutic range of vitamin K 12
warfarin 12
Antihypertensive medications, side effects of 105
Antiplatelets
agents 208
aspirin 1516
based on platelet function testing 17
ideal 15
inhibition of cyclic adenosine monophosphate (cAMP) 15
intravenous GPIIb/IIIa inhibitors 16
management of acute coronary syndromes (ACS) 15
noncardiac indications 15
platelet activation mechanism 15
prevention of stent thrombosis 15
P2Y12 inhibitors 1617
side effects 17
Antiplatelet therapy 212
Antithrombin III 12
Anti-Xa inhibitors 14
Aortic dissection 183, 228, 229 see also Thoracic aortic dissection
Aortic regurgitation
acute 1920
chest radiograph 20
chronic 1920
coronary angiography 20
CT aortogram 2021
ECG 20
echocardiogram 20
monitoring 2021
parameters of severity 21
pathophysiology 20
pharmacotherapy 21
risk of dissection or rupture 21
signs and symptoms 20
surgical management 21
transoesophageal echocardiogram of 20
Aortic root disease surgery 21
Aortic stenosis 183
annual surveillance 19
assessment of arterial tree 19
average survival rate 19
balloon valvuloplasty 19
complications 19
coronary angiography 19
ECG 18
echocardiogram measurements 18
exercise stress testing 1819
from congenital bicuspid valves 18
from senile calcification 18
indications for surgery 19
medical management 19
parameters of severity 19
prevalence 18
reasons for early development 18
risk stratification 1819
signs and symptoms 18
surgical valve replacement 19
transaortic valve implantation (TAVI) 19
voltage criteria 18
Apixaban 13, 213
Arrhythmias 199, 209
Arrhythmogenic cardiac syncope 216, 218
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
amiodarone therapy 37
beta-blocker therapy 37
cardiac transplantation 37
catheter ablation therapy 37
clinical presentation 34
definition 34
diagnostic criteria 36
early ‘concealed’ phase 35
early identification of asymptomatic carriers 37
ECG 35, 35
genes responsible for 34
implantation of cardioverter-defibrillator (ICD) 37
International Task Force criteria 36
mode of inheritance 34
pathological characterization 34
phenotypic expression 34, 36
prevalence 34
revised task force criteria (rTFC) 36
risk of sudden death 37
standard heart failure therapies 37
symptoms 35
T wave inversion 35
Arrhythmogenic RV dysplasia 93
Arterial access 163
Arterial blood gas 194
Arterial tortuosity syndrome (ATS)
aneurysms 66
skeletal and facial features 66
ARVC see Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ASA see Alcohol septal ablation (ASA)
Aspirin (acetylsalicylic acid) 1517
drug interactions 17
Asymmetrical septal hypertrophy 43
Asynchronous pacing modes 162
Athlete's heart
AV blocks 23
cardiac remodelling 2225
echocardiography 22
electrocardiographic abnormalities 22
electrocardiographic evidence of LVH 23
12-lead ECG 22
left ventricular wall thickness (LVWT) in 25
physiological ECG changes 2225, 2225
repolarisation anomalies 23
right bundle branch block (RBBB) 23
T-waves and J-point elevation 2324, 2324
Atrial fibrillation (AF) 1112, 45, 89, 114, 190, 199202, 212
alterations in atrial tissue 27
ambulatory ECG monitoring 28
antiarrhythmic agents 10
as age-dependent arrhythmia 12
assessment of bleeding risk 29
clinical conditions 27
clinical signs 200
closure 201, 202
consequences 28, 199200
ECG patterns 28, 28
echocardiographic assessment of 200
electrical phenomena initiating 27
Holter monitoring of 96
ILR detection of 97
incidence rate 27
left ventricular dysfunction 28
maintenance and restoration of sinus rhythm 29
oral anticoagulation therapies 29
‘pace and ablate’ strategy 29
patterns, definitions 27
pharmacological cardioversion 29
predisposing factors 27, 27
quality of life and exercise capacity in 28
rate control and anticoagulation strategy 2930
rhythm control strategies for 29
risk factors for strokes 2829
success rate of cardioversion 30
transoesophageal echocardiography (TOE) 28
transthoracic echocardiography 28
types 199
vascular dementia in 28
warfarin therapy 29
Atrioventricular node ablation 30
Autotriggered devices monitoring 97
AV blocks 23
B
Balloon valvuloplasty 19
Bazzett's formula 59
Beck's triad 2, 236
Beta-blockers 76, 113
classes 10
common side effects 10
control of arrhythmias 10
for abdominal aortic aneurysm 63
for angina 6
for aortic regurgitation 20
for atrial fibrillation 29
for catecholaminergic polymorphic ventricular tachycardia 62
for dilated cardiomyopathy 41
for heart failure 83, 89
for hypertrophic cardiomyopathy 45
for long QT syndrome 61
for restrictive cardiomyopathy 57
Bicuspid aortic valve (BAV)
calcification in 65
elective surgery 65
monitoring of 65
NOTCH gene mutation in 6465
risk factors for 65
Blalock–Taussig shunt 226
Blood pressure (BP), equation for calculating 103
Bosentan 110
Bradyarrhythmia 2223
British Association for Cardiovascular Prevention and Rehabilitation 196
BrS see Brugada syndrome (BrS)
Brugada syndrome (BrS)
causes 58
ECG pattern 59, 59
epicardial ablation of ventricular fibrillation 61
genes associated with 58, 61
incidence of 58
isopretenerol infusion 61
quinidine therapy 61
type 1 ECG pattern 61
Bubble contrast echocardiography 124
C
CABG see Coronary artery bypass grafting (CABG)
Calcium channel blockers 1011, 110
for angina 6
for heart failure with preserved ejection fraction 89
for hypertrophic cardiomyopathy 45
Calcium channels 89
Calcium scoring 112113
Cangrelor 16
Cardiac action potentials 89
Cardiac arrests
cardiopulmonary resuscitation (CPR) treatment 23
causes 1
epidemiology 1
4 H's and 4 T's of 1
in-hospital (IHCAs) 1
out-of-hospital (OHCAs) 1
Cardiac arrhythmias, diagnosis
cardiac monitoring methods 9697
12-lead ECG 96
Cardiac auscultation 194
Cardiac biomarkers 154
Cardiac catheterisation 40
arterial access routes 32
common indication 31
grading of severity 32
in electrophysiological studies 31
in investigation of valvular heart disease 31
postprocedural care 3233
pressure tracings and oxygen saturation, interpretation of 32
procedure 31, 31, 32
relative contraindications 31
risks of 32
risk-to-benefit ratio 31
Seldinger technique 32
Swan-Ganz catheter, use of 32
withdrawal of catheter 32
Cardiac computed coronary angiography 83
Cardiac contusion 237
Cardiac CT
acquisition of images 113
angiographic images of 112, 112
contrast bolus used 113
detectors 112
normal CT coronary angiogram 113
preparation of patients for 113
risks associated with 114
‘step and shoot’ technique 112
Cardiac magnetic resonance imaging 39, 40
Jacquier criteria 50
of HCM 4345, 44
of LVNC 50, 5152, 52
Petersen criteria 50
Cardiac monitoring methods 9697
Cardiac MRI 128
Cardiac myxomas 239, 240 see also Cardiac tumours
Cardiac rehabilitation 196198
core component 196, 196
defined 196
exercise-based 197198
improvement in 198
programmes 196, 198
referral rate 198
srategies for 198
Cardiac remodelling 2225
Cardiac tamponade, 236, 240
clinical signs 2
echocardiographic features of 2
needle pericardiocentesis procedure 2
pathognomonic signs of 2
pathophysiology 1
ventricular filling in 2
Cardiac transplantation 232235
absolute indications for 232
bicaval technique 233
cardiogenic shock 232
chronic rejection 233
contraindications to 233, 233
endomyocardial biopsy 233
hyperacute rejection 233
immunologic evaluation 232
nonischaemic cardiomyopathy 232
‘routine’ transplantation 232
symptom-limited metabolic stress test 232
urgent’ transplantation 232
Cardiac tumours 239242
cardiac CT 241
cardiac manifestations 240
cardiac metastases 240
cardiovascular magnetic resonance 241
echocardiography 241
embolic phenomena 240
hybrid imaging techniques 241
imaging examination 240241
malignant 239, 241242
myxoma 239
primary 239
secondary 239, 240
surgical resection 241
systemic manifestations 240
WHO histologic classification 239, 239
Cardiogenic shock 232
Cardiomyocyte potassium channels 8
Cardiomyocytes 8
Cardiopulmonary exercise testing (CPET) 171
Cardiopulmonary resuscitation (CPR) 23
Cardiopulmonary testing 45
Cardiovascular magnetic resonance (CMR) 150, 241
absolute contraindications to 115
bicuspid aortic valve, assessment of 118
biomarkers 149
blood flow assessment 115
cardiac perfusion assessment 115116
CHD, diagnosis and surveillance of 118
evaluation of IHD 117118
gadolinium-based contrast agent (GBCA), benefits of 115116
myocardial perfusion and viability assessment 116
of heart anatomy 115
of long- and short-axis cardiac cine imaging 115
of proximal coronary anatomy 116
parameters of cardiac masses, assessment of 118
patterns of gadolinium enhancement 117
pericardial disease, diagnosis and surveillance of 118
phenocopies of hypertrophic cardiomyopathy, identification of 116
regurgitant fraction 118
T1-mapping 116
valvular heart disease, diagnosis and surveillance of 118
volumetric analysis 115
Cardiovascular risk, calculators of 70
Cardioverter defibrillator 47
Carney syndrome 240
Carotid sinus massage 220221
Catecholaminergic polymorphic ventricular tachycardia (CPVT)
ambulatory ECG monitor 60
beta-blockers for 62
exercise ECG testing 5960
genes associated with 58, 62
incidence rate 58
ventricular fibrillation in 134
Catheter ablation 30
Catheter-directed thrombolysis 195
CFR see Coronary flow reserve (CFR)
CHA2DS2 VAS risk stratification system 29
Chagas’ disease 93
Channelopathies
Brugada syndrome (BrS) 58
catecholaminergic polymorphic ventricular tachycardia (CPVT) 58
causes 58
exercise restriction 62
genes associated with 5861
genetic causes 58
genetic screening 59
implantable cardioverter defibrillator (ICD) 61
12-lead ECG 59
lifestyle measures 61
long QT syndrome (LQTS) 58
medical therapy 61
risk of SCD 5859, 61
Chronic allograft vasculopathy (CAV) 234
Chronic mitral regurgitation 145
Cinchonism 9
Clopidogrel 1617
Cochrane database 198
Commotio cordis 236
Computed tomographic fractional flow reserve (CT-FFR) 5
Computed tomography coronary angiography (CTCA) 5
Conduction delays 150
Congenital heart disease (CHD) 197
Connective tissues
diseases 63
genetic and clinical characteristics of disorders 64
importance of 63
Constrictive pericarditis 55
Contrast agents 124
Coronary angiography
aortic regurgitation 20
aortic stenosis 19
Coronary artery bypass grafting (CABG) 7, 71, 114, 163
arterial conduits used 6869
comparison with PCI 6768
in acute NSTEMI 67
in acute STEMI 67
off-pump 68
on-pump 68
operation of 68
postoperative atrial fibrillation with 69
prognostic benefit 67
risk factors 69
survival benefits 67
team for carrying out 68
treatment of coronary disease with 67
trials and observational studies 6768
Coronary artery disease (CAD) 153155
antiplatelet agents 155
biomarkers 154
invasive coronary angiography 154
left ventricular failure 155
risk factor modification 155
Coronary flow reserve (CFR) 4
Coronary physiology testing 32
Coronary sinus defects 199
CPVT see Catecholaminergic polymorphic ventricular tachycardia (CPVT)
C-reactive protein (CRP) 140
CTCA see Computed tomography coronary angiography (CTCA)
CT coronary angiography 6, 40, 128
CT-FFR see Computed tomographic fractional flow reserve (CT-FFR)
Cutis laxa
aneurysms in 66
aortic dilatation in 66
arterial tortuosity in 66
skin features 66
X-linked 66
Cyanosis 200
Cyclic adenosine monophosphate (cAMP) 15
Cystic tumour of atrioventricular node 240
Cytochrome P450 (CYP) enzyme system 179
D
Dabigatran 1314, 213
DAPT see Dual antiplatelet therapy (DAPT)
DCM see Dilated cardiomyopathy (DCM)
Deep vein thrombosis (DVT) 12
Depolarisation 8
Desmocollin-2 (DSC-2) 34
Desmoglein-2 (DSG-2) 34
Desmoplakin (DSP) 34
D-fenfluramine 108
Diabetes mellitus (DM)
angioplasty 71
cardiovascular risk management 7071
coronary artery bypass grafting 71
coronary events 72
EMPA-REG outcome trial 71
glycaemic control 7071
hyperglycaemia 70
hyperglycaemia in 70
incidence of heart failure 72
insulin therapy 7071
intensive control of glycaemia in 70
LEADER study 71
lifestyle modification and 70
metformin therapy 7172
prevalence of hypertension 71
risk factor for CVD 70
risk management 70
screening tests 70
SGLT-2 inhibitors 72
‘silent’ or painless MI 70
statin therapy 71
thiazolidinediones 72
type 1 (T1DM) 70
type 2 (T2DM) 70
Diabetic cardiomyopathy 72
Diagnostic angiography 32
Dihydropyridine calcium channel blocking agents 11
Dilated cardiomyopathy (DCM)
angiotensin-converting enzyme (ACE) inhibitor therapy 41
anticoagulation therapy 41
approaches to diagnosis 39
beta-blocker therapy 41
cardiac biopsy 39
cardiac catheterisation 40
cardiac magnetic resonance imaging 39, 40
cardiac resynchronisation therapy 41
causes 38
characteristics 38
chemotherapeutic agents for 38
clinical spectrum 38
definition 38
diuretic therapy 41
ECG anomalies 39
echocardiogram 39
endomyocardial biopsies 40
ethanol-induced 41
etiology 38
familial (genetic) 38
familial evaluation 39
genetic mutations in 38
genetic screening 3940
histological features of 39
hydralazine therapy 41
ICD implantation 41
idiopathic 40
immunosuppression therapy 41
ivabradine therapy 41
12-lead ECG 40
neprilysin inhibitor therapy 41
pathogenic mechanisms of 3839
peripartum 38
prevalence 38
progressive heart failure, risk of 41
risk of arrhythmias 39
serological criteria for diagnosis 39
signs and symptoms 39
steroid therapy 41
sudden death, risk of 41
symptoms and signs 39
thromboembolism, risk of 41
titin mutations in 38
Diltiazem 11
Dipyridamole 1617, 126
Disopyramide 10
Dobutamine 126
Dobutamine stress echocardiography 123124
Dual antiplatelet therapy 208
Dual antiplatelet therapy (DAPT) 1516, 173
Duplex ultrasonography (DUS) 175
DVT see Deep vein thrombosis (DVT)
Dyslipidaemia 99
classification 99100
drug combinations for 101
Dyspnoea 17
E
Early repolarisation pattern, in athletes 23
ECG patterns 123
arrhythmogenic right ventricular cardiomyopathy 35, 35
atrial fibrillation 28, 28
dilated cardiomyopathy 39, 40
European Society of Cardiology (ESC) criteria 24
exercise stress testing 79
heart failure 81
hypertrophic cardiomyopathy 4243, 43
idiopathic pulmonary arterial hypertension 108, 109, 110
implantable cardioverter-defibrillator 131132
in athletes 2425, 2425
international recommendations, in athletes 2425, 25
juvenile 23, 24
right ventricle dynfunction 94
ECG stress test 5
Echocardiogram of HCM 43
Edoxaban 213
Ehlers–Danlos syndrome (EDS)
aortic dilation in 65
arthcochalasia type 65
classic type 65
clinical features 65
dermatosparaxis type 65
gene mutations in 65
hypermobility type 65
joints and skin manifestations in 65
kyphoscoliosis type 65
risk of arterial aneurysms and/or dissections 65
vascular type 65
Electrical cardioversion 30
Electrical remodelling, in athletes 2224
EMF see Endomyocardial fibrosis (EMF)
Empagliflozin 71
Endomyocardial fibrosis (EMF) 54, 93
Endovascular stent–grafts 230
Enzyme lipoprotein lipase (LPL) 139
Epoprostenol 110
Eptafibatide 15
European Society of Cardiology (ESC) 150
Event recorders see also Holter monitoring; Implantable loop recorders (ILR)
clinical investigation of syncope 97
comparison with Holter monitors 97
discomforts 97
Exercise capacity 78
Exercise ECG 45
Exercise stress echocardiography 123124
Exercise stress testing 6, 144
BP abnormalities, interpretation of 78
cardiopulmonary 82, 88
common indications 77
contraindications 78
ECG changes 79
fatigue and functional capacity, assessment of 78
HR abnormalities, interpretation of 78
incidence of myocardial infarction 79
modalities 76
patient preparation 76
prerequisites and requirements 76
principal reasons for 77
probability of CAD 79
procedure 7779
Q-waves 79
recovery period 76
secondary complications 79
selection of workload 76
ST-segment readings, interpretation of 77, 79
termination of 78
treadmill protocol 76
warm-up period 76
F
Femoral access 163
Fenfluramine 108
Fibromas 239 see also Cardiac tumours
Flecainide 10, 29, 62
Fractionated heparins 1213
G
Glyceryl trinitrate (GTN) 113
GPIIb/IIIa inhibitors 16
H
Hampton's hump 194
HAS-BLED risk system 29
HCM see Hypertrophic cardiomyopathy (HCM)
Heart failure (HF)
ACE inhibitors 83, 89
adaptation mechanisms 80
ambulatory electrocardiographic monitoring 82
angiotensin receptor antagonists 84
angiotensin receptor neprilysin inhibitor (ARNI) therapy 84
average age at first diagnosis 80
beta blockers 83, 89
blood tests 82
BNP and NT-proBNP levels in 8182
cardiac resynchronisation therapy 85
cardiovascular magnetic resonance imaging 82
causes 81
chest X-ray findings in 81
coronary angiography 83
coronary revascularisation 85
digoxin therapy 84
diuretics 84
ECG 81
echocardiography 82
endomyocardial biopsy 83
exercise testing 82
genetic screening 83
hydralazine and isosorbide dinitrate (H-ISDN) therapy 84
ICD and 85
in diabetes mellitus (DM) 72
ivabradine therapy 84
mineralocorticoid aldosterone antagonists (MRA) 8384
morbidity and mortality 80
New York Heart Association (NYHA) functional classification 81
objective of treatment 83
prevalence 80
rate of hospital readmission 80
stress echocardiography 83
symptoms and signs 82
transplantation of heart 85
urinalysis 82
ventricular-assist devices 85
with preserved ejection fraction (HFpEF) 80, 87
with reduced ejection fraction (HFrEF) 80
Heart failure with preserved ejection fraction (HFpEF) 80, 87
alterations in cardiac function 87
assessment of LV 8788
BNP and NT-proBNP levels 88
clinical diagnosis 8889
comorbidities associated with 87
comorbidity burden 89
diastolic function abnormalities 88
diuretics therapy 89
echocardiography 8788
ejection fraction 87
exercise functions, abnormalities in 87
exercise testing 88
hospitalisation 89
impaired prognosis 87
left ventricular (LV) diastolic dysfunction in 87
medications 89
mortality rates 89
noncardiovascular factors 89
prevalence of 87
recommended lifestyle changes 89
symptoms 87
tissue Doppler imaging (TDI) 88
Heparin-induced thrombocytopaenia 13
High-intensity interval training (HIIT) 198
protocols 198
Holter monitoring 96 see also Event recorders; Implantable loop recorders (ILR)
clinical indications for 96
detection rate of AF 96
device 96
diagnosis of arrhythmic vs nonarrhythmic palpitations 96
discomforts 97
Human leukocyte antigen (HLA) 232
Hurler's syndrome 143
Hydralazine 41
Hypercholesterolaemia
alirocumab therapy 102
asymptomatic features 101
causes 99
cholesterol levels 99
definition 99
evolocumab therapy 102
familial 99, 102
HDL as prognostic indicator 100
lipid profile screening 99, 101
lipoprotein metabolism in 99, 100
nonpharmacological measures 101
PCSK9 inhibitors 102
pharmacological interventions 101, 101102
plant sterols for 101
recommended diet 101
risk estimation 101
risk of CV 100101
WHO/Fredrickson classification 99100
Hypertension
cardiovascular complications 105106
causes 103
Doppler ultrasound 104
drug therapy 104105, 105
laboratory tests 104
12-lead ECG 104
lifestyle interventions 104
modifiable risk factors 103
neurological complications 106
nonmodifiable risk factors 103
ocular complications 106
prevalance 103
renal complications 106
renin–angiotensin–aldosterone system (RAAS) activation 103
screening tests 104
signs and symptoms 103104
systolic and diastolic pressures, values for 103104
toxicology evaluation 104
Hypertensive emergency/Hypertensive urgencies 106
Hypertrophic cardiomyopathy (HCM) 25
AF recurrences in 4546
alcohol septal ablation (ASA) 46
ambulatory ECG 45
amiodarone therapy 45
anticoagulation therapy 45
beta-blocker therapy 45
calcium-channel blocker therapy 45
cerebrovascular accidents in 46
changes in left ventricular (LV) filling in 42
classic auscultatory finding for 42
CMR suggestive of 4345, 44
diastolic dysfunction in 42
disopyramide therapy 45
echocardiogram of 43
exercise ECG 45
genetic screening 45
ICD in 46
inherited cardiovascular conditions 42
12-lead ECG 4243, 43
LVOT obstruction in 42
LV septal thickness 43
phenotypic expression of 45
physical examination 42
prevalence 42
risk factors 46
septal to posterior free wall ratio 43
structural microvasculature abnormalities in 42
sudden death risk 4546
surgical myectomy 45
systolic and diastolic functions 43
warfarin therapy 45
Hypoxia 195
I
ICD see Implantable cardioverter-defibrillator (ICD)
Idarucizumab 14
Idiopathic pulmonary arterial hypertension
blood tests 108
chest radiograph 108, 109
CT scan 108, 109
definition 107
ECG 108, 109, 110
echocardiography 108, 109, 110
hallmark of 107
incidence 107
mean pulmonary artery pressure 110
multidisciplinary approach to diagnosis 110
signs and symptoms 108
vasoreactivity testing 110
IHCA see In-hospital cardiac arrests (IHCAs)
ILR see Implantable loop recorders (ILR)
Implantable cardioverter-defibrillator (ICD) 37, 41, 46, 57, 61, 83, 85, 94
‘burst’ ATP 132
components 131132
defibrillation safety margin test 132
driving restrictions 133
ECG 131132
ESC recommendations for secondary and primary prevention 130131
evidence-based indications for 130
exercise restrictions 133
likelihood of defibrillating 132
monomorphic VT 132, 133
pacing parameters 131
patients considered for 130131
procedure for implantation 131132
prophylactic 131
‘ramp’ ATP 132
restrictions imposed with 62
risk of procedural complications 62, 131133
shocks 132
TV ventricular 131
wearable 132
Implantable cardioverter-defibrillator (ICD) devices 159
Implantable loop recorders (ILR) 97 see also Event recorders; Holter monitoring
clinical investigation of syncope 97
cost per diagnosis 97
detection of AF 97
diagnostic yield of 97
discomforts 97
indications for 97
Incremental cost-effectiveness ratio (ICER) 198
Infective endocarditis
antibiotic prophylaxis 75
blood cultures 74
drug treatment 74
echocardiography 73, 7374
endocarditis team, role of 75
formation of nonbacterial thrombotic endocarditis (NBTE) 73
guidelines for prevention 75
modified Duke criteria 74
mortality and morbidity 73
multislice computed tomography (MSCT) 74
nuclear imaging techniques 74
surgical management 7475
symptoms 73
Inferior sinus venosus defects 199
In-hospital cardiac arrests (IHCAs) 1
INR see International normalised ratio (INR)
International Diabetes Federation (IDF) 139, 139
International normalised ratio (INR) 12
Intravascular ultrasound (IVUS) 164
Invasive coronary angiography 114, 144145, 154
Ischaemic cardiomyopathy 72
Ischaemic heart disease (IHD) 196, 216
Ischaemic stroke 210
anticoagulation 212213
antiplatelet therapy 212
atrial fibrillation 212
cholesterol-lowering medication 212
intravenous thrombolysis 210
large artery stenosis 211
Ivabradine 41
J
J-point elevation, in athletes 23
Jugular venous pressure (JVP) 167
Junctional plakogolbin (JUP) 34
JUP see Junctional plakogolbin (JUP)
Juvenile ECG pattern 23, 24
K
Kusmaul's sign 236
L
Lansoprazole 17
Left atrial catheter ablation 30
Left cardiac sympathectomy 61
Left coronary cusp (LCC) 65
Left ventricular assist device (LVAD) therapy 57
Left ventricular ejection fraction (LVEF) 5
Left ventricular hypertrophy (LVH) 5
voltage criterion for 23, 24
Left ventricular noncompaction cardiomyopathy (LVNC)
anticoagulation therapy 52
cardiac MRI criteria 50, 5152
clinical diagnosis 47
clinical manifestations 47
compacted and noncompacted myocardium, measurements of 50
diagnostic criteria 4850, 49
echocardiographic criteria for 4850, 49, 49
genetic familial screening 52
genetic mutations in 48
heart failure and 48
in asymptomatic athletes 48
LV systolic dysfunctions in 47
multimodal diagnostic approach 52
myocardial compaction 48
myocardial strain values in 50
myocardium in 4748
pharmacological treatment 52
preclinical phase 48
prevalence 47
prognosis 52
systemic neuromuscular diseases associated with 48
trabecular mass-to-total mass ratio 50
T-wave inversion 48
Left ventricular systolic dysfunction 199
Leucocytosis 194
Lidocaine 10
Loeys–Dietz syndrome 65
Long QT syndrome (LQTS)
beta-blockers for 61
clinical diagnostic scoring system for 61
genes associated with 5859
incidence rate 58
12-lead ECG 60
QTc durations in 5859
T-wave morphology in 59
Low molecular-weight heparin (LMWH) 13
side effects 13
LQTS see Long QT syndrome (LQTS)
LVAD therapy see Left ventricular assist device (LVAD) therapy
LVEF see Left ventricular ejection fraction (LVEF)
LVH see Left ventricular hypertrophy (LVH)
LVNC see Left ventricular noncompaction cardiomyopathy (LVNC)
M
Marfan syndrome (MFS)
aneurysm in 63
angiotensin II receptor blockers for 63
beta-blockers for 63
Ghent criteria for 63, 65
growth of aorta 66
mitral valve prolapse (MVP) in 63
MASS phenotype
aortic dilatation in 66
Ghent criteria for 66
skin and skeletal features 66
Metabolic syndrome 139141
components of 141
c-reactive protein 140
defined 139
elements of 141
hyperinsulinaemia and hyperglycaemia 140
insulin resistance syndrome 139
primary management 140, 141
pro-inflammatory state 140
pro-thrombotic state 140
risk factors for 140
secondary management 141, 141
Syndrome ‘X’ 139
Mexiletine 10
Mitral regurgitation 145147
Mitral stenosis 31, 143145, 183
Mitral valve disease 143147
complications of 144
echocardiographic markers of severity 146
morphology 144
obstruction of 143
Mitral valve prolapse
echocardiogram 64
heart sound in 64
prognosis of 64
treatment 64
Mobitz type 1 and 2 AV block 23
Moderate intensity continuous exercise (MICE) 198
MPS see Myocardial perfusion scintigraphy (MPS)
Mycophenolate mofetil (MMF) 234
Myectomy 45
Myocardial infarction (MI) 1, 90, 92, 130
diagnosis 2
in DM 7071
Myocardial ischaemia 4, 7
investigative tests for 6
Myocardial pacemaker 184
Myocardial perfusion scintigraphy (MPS) 126
advantages 128
diagnostic values 127
radiation risks 128
Myocarditis 148152
acute fulminant 152
biomarkers 149150
biopsy-documented 149
Dallas criteria 151
defined 151
echocardiography 150
electrocardiogram 150
giant cell 152
histological criteria 148
ICD implantation 152
immunohistochemical criteria 148
immunological criteria 148
immunomodulation 152
lymphocytic 148
saddle-shaped ST elevation and PR depression 150
sarcoidosis 152
Troponin 149
with inflammatory heart muscle disease 149
Myopericarditis 149
N
N-acetyl procainamide (NAPA) 9
NAPA see N-acetyl procainamide (NAPA)
National Institute for Health and Care Excellence (NICE) 179
National Institutes of Health Stroke Scale (NIHSS) score 211
National Surgical Quality Improvement Program (NSQIP) database 171
Needle pericardiocentesis 3
Neurocardiogenic syncope 216217
NOACs see Novel oral anticoagulants (NOACs)
Nonalcoholic fatty liver disease (NAFLD) 141
Noncoronary cusp (NCC) 65
Nonsteroidal anti-inflammatory drug (NSAID) 13, 104
Non-ST-segment elevation myocardial infarction (NSTEMI) 1, 67, 153
Nonsyndromic genetic mutations 199
Novel oral anticoagulants (NOACs) 13
NSAID see Nonsteroidal anti-inflammatory drug (NSAID)
NSTEMI see Non-ST-segment elevation myocardial infarction (NSTEMI)
Nuclear cardiology techniques 126
diagnostic values 127
identification of cardiovascular events 127
patient preparation 126
radiation risks 128
sensitivity and specificity 127
SPECT g-cameras 126
tracers used 126127
vasodilators used 126
Nonsustained ventricular tachycardia (NSVT) 223 see also Ventricular tachycardia (VT)
O
Obesity 139
OHCA see Out-of-hospital cardiac arrests (OHCAs)
Omeprazole 17
Optical coherence tomography (OCT) 164
Ostium primum defects 199
Ostium secundum defects 199
Out-of-hospital cardiac arrests (OHCAs) 1
P
Pacemaker
myocardial 184
Pacemakers 157162
atrioventricular node 158
base rate 162
biventricular 157
CRT implants 160
extrathoracic axillary route 160
heart block 158
His-Purkinje fibres 158
implantation and replacement rates 157162
left bundle branch block 159, 159
MRI-conditional devices 159
pacing parameters 161, 161
programming 161162
programming changes 162
right ventricular outflow tract (RVOT) 160
sinus node disease 157158
superior vena cava 160
systolic heart failure 158159
troubleshooting 161162
Pansystolic murmur 200
Pantoprazole 17
Papillary fibroelastomas 239 see also Cardiac tumours
Paradoxical embolism 199
Paroxysmal AF 27, 28
PCI see Percutaneous coronary intervention (PCI)
Percutaneous coronary intervention (PCI) 7, 67, 163165
clopidogrel 164
femoral access 163
intracoronary imaging 165
iodine-based contrast 163
MACCE rate of 165
pressure wire 165
rotablation 164
Seldinger technique 163
stable angina 163
SYNTAX score 164
ticagrelor 164
vascular access site 165
Perfusion tracers see also Nuclear cardiology techniques
18F-fluorodeoxyglucose (18F-FDG) PET 128
18F-flurpiridaz 128
18F-sodium fluoride 128
99mTc-pertechnetate 127, 127
99mtechnetium (99mTc) 127
201Thallium (201Tl) 126127
Pericardial effusion 108
Pericardiocentesis 242
Pericarditis 166169
acute 166
asymptomatic effusion 168
cardiac biomarkers 167
causes of 166, 166
constrictive 168
ECG 168
echocardiogram 168
episodes of inflammation 166167
features 168
inflammatory markers 167
pericardial effusions 169
saddle-shaped’ ST-segment elevation 168
sympathetic outflow 166
Perioperative cardiac events
associated risk 170
ECG abnormalities 172
interventions 170
pharmacological optimisation 171
Peripheral artery disease (PAD) 174177
ankle brachial pressure index 176, 176
ankle–brachial pulse index 175
Fontaine classification 176
hypertension 176
ischaemic limb 177
lifestyle modification 176
limb amputation 174177
limb salvag 177
Rutherford classification 176
smoking cessation 177
treatment algorithm for 177
vascular imaging 175
PET-MRI 128
Pharmacological cardioversion 29
Pharmacological stress test 6
Plakophillin-2 (PKP-2) 34
Plaque rupture 1
Polycystic ovary syndrome 140
Polypharmacy 179181
defined 179
pharmacokinetic interactions 179, 180
physiochemical interactions 179
risk of 179180
Postural tachycardia syndrome (POTS) 216
Potassium channel blockers 10
Prasugrel 16
Pregnancy
aortic dissection 183
dilated cardiomyopathy 183
ionising radiation 182
obstructive lesions 183
peripartum cardiomyopathy 183
risk scores 182
warfarin anticoagulates 184
Presyncope 23
Preventive cardiology
blood pressure 186
cardioprotective pharmacotherapy 187
diabetes mellitus 186
diet and nutrition 186
lipids 187
polypill 187
psychosocial support 187
risk assessment 185186
role of antithrombotics 187
smoking cessation 186
weight control 186
Procainamide 910
Propafenone 10, 29
Prosthetic heart valves 189191
anticoagulation 190
autografts 189
bioprosthetic valves 190
haemolysis 191
homografts 189
signs 190
thrombogenicity of prosthetic valve 191
transcatheter implantable prosthesis 189
valve failure 191
valvular thrombosis 191
xenografts 189
Prosthetic valves 183
Protamine sulphate 13
Pseudosyncope 216
Pulmonary arterial hypertension 197
anorexigen-induced 108
calcium channel blockers (CCBs) 110
conditions 107
consideration for transplantation 110
definition 107
endothelin receptor antagonists (ERAs) 110
genetic screening 108
hallmark of 108
heritable 108
imaging modalities 108, 109
lifetime risk of developing 108
New York Heart Association (NYHA) recommended treatment 111
phosphodiesterase V inhibitors 110
salvage procedure 110
targeted therapies 110
Pulmonary embolism 1, 12
Pulmonary embolism (PE) 193195
ECG abnormalities 194
incidence of 193
risk factors for 193, 193
V/Q scan 194
Well's criteria for 194
Pulmonary hypertension 31, 199
Pulsus parodoxus 236
Pyridostigmine 10
Q
QCA see Quantitative coronary angiography (QCA)
Quality-adjusted life year (QALY) 198
Quantitative coronary angiography (QCA) 32
Quinidine 9, 61
R
RBBB see Right bundle branch block (RBBB)
RCM see Restrictive cardiomyopathy (RCM)
Regadenoson 126
Regurgitant tricuspid 93
Repolarisation anomalies, in athletes 23
Restrictive cardiomyopathy (RCM)
acquired 55
angiotensin-converting enzyme inhibitors for 57
anticoagulation therapy 57
beta-blocker therapy 57
blood and urine examinations 56
cardiac catheterisation 56
causes 54
classification 54
CMR or CT imaging 5556
common form 54
conduction abnormalities 56
corticosteroid therapy 57
definition 54
diagnostic framework for 55
diastolic and systolic volumes in 54
diuretic therapy 57
ECG 56
echocardiogram 56
endocardiectomy 57
familial 55
genetic testing 56
imatinib therapy 57
implantable cardioverter defibrillator (ICD) 57
left ventricular assist device (LVAD) therapy 57
malignant ventricular arrhythmias, risk for 56
nonfamilial 55
nuclear imaging 56
pacemaker implantation 57
prevalence 54
prognosis 56
risk of developing AF 56
risks in paediatric patients 56
severity grading 55
sudden death risk 56
symptoms and signs 55
thromboembolic complications 56
valve replacement 57
ventricular physiology in 54
Revascularisation 67, 163
Rhabdomyomas 239, 240
Rhabdomyosarcomas 239
Right bundle branch block (RBBB) 23
Right coronary cusp (RCC) 65
Right ventricle (RV) dysfunction
antiarrhythmic agents 94
caloric supplementation 94
cardiac and lung transplantation 94
causes 93
Chagas’ serology tests 94
chest X-ray 94
digoxin therapy 94
diuretic therapy 94
heart sound 94
imaging modalities 94
implantable cardiac defibrillators 94
laboratory testing 94
12-lead ECG 94
phosphodiesterase type 5 inhibitors for 94
prostaglandin analogues for 94
pulmonary investigations 94
Q waves 94
risk of sudden death 94
role in cardiovascular diseases 93
ST/T changes 94
supportive care 94
symptoms 9394
Right ventricle hypertrophies 107
Right ventricular outflow tract (RVOT) 58, 61
Rivaroxaban 213
Rivoroxiban 13
Rotational atherectomy 164
S
Sarcomas, cardiac 239
SCD see Sudden cardiac death (SCD)
Schwartz score 61
Secundum defects 200
Short QT syndrome 58
Single-photon emission computed tomography (SPECT) 126
Situational syncope 216217
Sodium channel blockers 1011
Sodium channels 8
Sotalol 10
SPECT g-cameras 126
Staphylococcus aureus infection see Infective endocarditis
Statins 172
ST-elevation myocardial infarction (STEMI) 207209
arrhythmias 209
atypial symptoms 207
echocardiogram 208
exercise-based rehabilitation programmes 209
STEMI see ST-segment elevation myocardial infarction (STEMI)
Stent thrombosis 165
Stress echocardiography 128
Stress tests 5
Stroke 210
ST-segment elevation myocardial infarction (STEMI) 1, 67, 153
Sudden cardiac death (SCD) 37, 130
in arrhythmogenic right ventricular cardiomyopathy 37
in channelopathies 5859
in hypertrophic cardiomyopathy 46
risk features for 37
Superior sinus venosus defects 199
Supraventricular tachycardia (SVT) 219222
differential diagnosis 221
diltiazem and verapamil 221
electrophysiology (EP) studies 222
initial management of 222
intravenous adenosine 221
invasive electrophysiology study 220
irregular narrow complex tachycardias 220
12-lead ECG 220
paroxysmal 219
pathophysiology of 219, 219
regular narrow complex tachycardias 220
synchronised cardioversion 222
telemetry monitoring 220
vagal manoeuvres 220221
Surgical ablation 30
Surgical aortic valve replacement 21
SVT see Supraventricular tachycardia (SVT)
Syncope 216218
causes of 216218
incidence of 216218
SYNTAX score 164
Systemic lupus erythematosus (SLE) 910
T
Tachycardia
supraventricular 219222
ventricular 223224
TAVI see Transcatheter aortic valve implantation (TAVI)
T2DM see Type 2 diabetes mellitus (T2DM)
Tetralogy of Fallot (TOF) 225227
adult patients with 225
anatomic features 225
boot-shaped heart 226
complications 226227
exercise testing 226
fatal arrhythmias risk 227
in infancy 225
intracardiac surgical primary repair 226
serial aortic root measurements 227
transthoracic echocardiography 226
ventricular septal defect in 225
Thoracic aortic aneurysm/dilatation 6566
familial 6566
gene mutations in 6566
growth of aorta 66
Thoracic aortic dissection 228231
angiography/aortography 230
blood pressure control 230
chest pain in 228
chest radiography 229
CT angiography 229230
ECG 229
endovascular repair 230
MR angiography 230
risk factors 228, 229
Stanford system of classification 228
transoesophageal echocardiography 229
type A 228, 230
type B 228, 230
Thromboembolic disease 184
Thrombosis, causes 12
Thromboxane A2 (TXA2) 15
Ticagrelor 1617
TIDM see Type 1 diabetes mellitus (T1DM)
Tirofiban 15
Tissue Doppler imaging (TDI) 122, 122
TOE see Transoesophageal echocardiography (TOE)
TOF see Tetralogy of Fallot (TOF)
Torsade de pointes 224 see also Ventricular tachycardia (VT)
Transcatheter aortic valve implantation (TAVI) 19, 114
Transient ischaemic attack (TIA) 210
Transoesophageal echocardiography 144
Transoesophageal echocardiography (TOE) 28, 73, 74, 82, 124, 124, 200, 229
Transthoracic echocardiography 154, 194, 200
Transthoracic echocardiography (TTE) 120
approach to data acquisition and interpretation 122
Colour flow Doppler mode 122
common indications for 123
continuous wave (CW) 120, 121
disadvantages 123
Doppler mode 120
in acute medicine 123
M-mode 120, 121
patient preparation 122
pulsed wave (PW) 120, 121, 122
risks and challenges 123
TDI 122
two-dimensional (2D) 120, 120
Traumatic heart disease 236237
blunt trauma 236
cardiac tamponade 236
complications 236237
continuous cardiac monitoring 237
echocardiography 237
penetrating trauma 236
thoracotomy 237
Treprostinil 110
Tumours, cardiac 239242 see also Cardiac tumours
T-wave inversion, in athletes 2324, 24
Type 1 diabetes mellitus (T1DM) 70 see also Diabetes mellitus (DM)
angiotensin-converting enzyme inhibitors 71
cardiovascular outcomes in 70
insulin therapy 71
prevalence of hypertension 71
statin therapy 71
Type 2 diabetes mellitus (T2DM) see also Diabetes mellitus (DM)
angiotensin-converting enzyme inhibitors 71
insulin resistance 70
insulin therapy 71
prevalence of hypertension 71
risk factors for CVD 70
statin therapy 71
U
Ultrasound contrast agent 124
Unfractionated heparin 13, 32
Unprovoked syncope 217
V
Ventricular fibrillation (VF) 130
Ventricular septal defects (VSDs) 203206
anatomical classification 203
aortic regurgitation 206
arrhythmias 206
cardiac catheterisation 205
direction and magnitude 204
echocardiography 205
Eisenmenger phenomenon 204
indications for intervention 205
infective endocarditis 206
inlet 203
muscular 203
outlet 203
perimembranous 203
subpulmonary stenosis 206
tricuspid regurgitation 206
Ventricular tachycardia (VT) 223224
catheter ablation 224
coronary arteriography 223
defibrillation 224
generation of 223
intravenous amiodarone or lidocaine 224
12-lead ECG 223
monomorphic 224
nonsustained 223
polymorphic 224
sustained 223
with haemodynamic instability 224
Verapamil 11
Virchow's triad 12, 193
Vitamin K consumption, stable 12
Vitamin K-dependent clotting factors (II, IV, IX and X) 12
VT see Ventricular tachycardia (VT)
W
Warfarin 12, 29, 45, 213
for atrial fibrillation 29
for hypertrophic cardiomyopathy 45
reversal of 13
side effects 13
Westermark sign 194
Wolff–Parkinson–White syndrome 216
World Health Organization 196
X
X-linked cutis laxa 66
×
Chapter Notes

Save Clear


Advanced life support1

 
Key points
  • Cardiac arrest may occur as a result of several cardiac disorders including acute coronary syndrome, cardiomyopathy, congenital heart disease, ion channel diseases and valvular heart disease and cardiac tamponade
  • Effective chest compressions and early defibrillation when appropriate are crucial for optimal outcomes in a cardiac arrest
  • In the setting of a cardiac arrest, the expertise of a cardiologist is required for the delivery of prompt and safe revascularisation in the context of atherosclerotic coronary artery disease, or pericardiocentesis in the case of cardiac tamponade, as well as guidance for subsequent therapy in survivors of cardiac arrest from other cardiac diseases
 
Epidemiology
The majority of out-of-hospital cardiac arrests (OHCAs) in the UK occur at home, with only 20% of OHCA occurring in public places. In both OHCAs and in-hospital cardiac arrests (IHCAs), the initial rhythm is usually non-shockable (pulseless electrical activity or asystole), with only 20% of IHCAs initiated by a shockable rhythm (ventricular fibrillation/pulseless ventricular tachycardia).
 
Pathophysiology
The main causes of a cardiac arrest are the 4 H's and 4 T's: hypoxia, hypovolaemia, hypothermia, hypo- and hyperkalaemia, thromboembolic (pulmonary embolism/myocardial infarction), toxins, tension pneumothorax and tamponade.
This chapter focuses on atherosclerotic coronary artery disease and cardiac tamponade.
 
Atherosclerotic coronary artery disease
The acute coronary syndrome (ACS) incorporates unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). Whilst the clinical presentation of each of these conditions differs, the underlying pathophysiological process remains similar – myocardial ischaemia due to mismatch between myocardial oxygen supply and demand and additionally, in myocardial infarction (MI), the presence of myocyte necrosis. The underlying cause of ACS is often atherosclerotic plaque rupture resulting in an acute reduction of the coronary lumen patency. Plaque rupture initiates a cascade of events including distal embolisation of the plaque into the coronary vessel, acute thrombosis within the coronary artery and also into the ruptured plaque, and also vasoconstriction of the smooth muscle cells surrounding the coronary artery. ACS may also occur in the presence of increased physiological stress, due to an increase in myocardial oxygen requirements. Disease conditions resulting in a demand–supply mismatch of myocardial oxygenation include anaemia, sepsis, tachy- and bradyarrhythmias, and respiratory failure.
 
Cardiac tamponade
During a cardiac arrest, particularly in the setting of trauma, postcardiac surgery, myocardial rupture or aortic dissection, there should be a high degree of suspicion for cardiac tamponade. Accumulation of fluid, gas or clot in the pericardial space results in increased pericardial pressure. When this pressure exceeds intracardiac pressure in the atria and ventricles, impaired cardiac filling ensues which can result in cardiac tamponade, and ultimately, cardiac arrest. Both the volume of fluid/gas/clot and the rate at which it accumulates in the pericardial space are important in the propensity for developing cardiac tamponade. A small volume of fluid/gas/clot that accumulates quickly can result in tamponade because of the rapid increase of pressure in the pericardial space.2
 
Clinical features
 
Atherosclerotic coronary artery disease
The clinical features of ACS are described in the atherosclerotic heart disease chapter; however, the main symptom of ACS is chest pain/tightness that may radiate to the arms, neck, back or upper abdomen. Breathlessness, a more atypical symptom of ACS, is seen particularly in women, the elderly and diabetic patients.
 
Cardiac tamponade
The pathognomonic signs of cardiac tamponade are referred to as ‘Beck's triad,’ comprising of muffled heart sounds, hypotension – pulsus paradoxus (>20 mmHg difference in systolic blood pressure between inspiration and expiration) and a raised jugular venous pressure; however, these clinical signs may not always be present in tamponade, e.g. in hypovolaemic states.
 
Investigations and diagnosis
 
Atherosclerotic coronary artery disease
The diagnosis of ACS is made in the setting of typical symptoms of chest pain and ECG changes involving the ST-segment and/or T wave, or the development of left bundle branch block (LBBB). The diagnosis of MI is made with a cardiac biomarker, e.g. high sensitivity troponin, elevated above the 99th centile, in combination with any one of the following: typical symptoms; ECG changes of the ST-segment or T wave, Q waves or LBBB; regional wall motion abnormality on imaging or loss of viable myocardium; or the presence of intracoronary thrombus on angiography or postmortem.
 
Cardiac tamponade
The diagnosis of cardiac tamponade is made by echocardiography. The most easily identifiable findings include atrial and then ventricular collapse during systole and diastole respectively. The lowest pressure chambers of the heart (right sided) are affected first.
During inspiration, there is a reduction in intrathoracic pressure. This accentuates venous return to the heart, and hence increases right ventricular (RV) filling. The increased pulmonary compliance that additionally occurs during inspiration also contributes to the increased blood pool in the lungs and reduces pulmonary venous return to the left ventricular (LV). The reduced LV filling results in reduced stroke volume, and hence reduced systolic blood pressure. Conversely in expiration, with an increase in intrathoracic pressure, LV filling is increased. In cardiac tamponade, this respiratory variation is more marked with >25% variation across the mitral valve (MV) and >40% variation across the tricuspid valve (TV) and can be visualised with pulsed wave Doppler measurements. Additional echocardiographic features include abnormal septal motion with respiration (septal movement towards the LV in inspiration and towards the RV in expiration); dilated inferior vena cava with <50% collapse with inspiration (due to increased RA pressure); increased flow reversal in expiration in the pulmonary veins and increased flow reversal in inspiration in the hepatic veins.
In the setting of a cardiac arrest, echocardiographic features of tamponade will be absent. Focussed ultrasonography identifying pericardial fluid should prompt consideration of pericardiocentesis. In the setting of postcardiac surgery or chest trauma, resuscitative thoracotomy should be considered. The Resuscitation Council UK recommend ultrasonography using a subxiphoid approach, during the 10 seconds when pulse check is being performed and when chest compressions are halted to avoid delaying the delivery of effective cardiopulmonary resuscitation (CPR).
 
Treatment
 
Cardiac arrest
The Resuscitation Council UK algorithm for delivering advanced life support focusses on providing effective and prompt CPR, with emphasis on delivering good quality chest compressions, and where appropriate, early defibrillation. The 2015 ALS guidelines state that during CPR with an unprotected airway, two ventilations should be given after each sequence of 30 chest compressions. Once a tracheal tube or supraglottis airway device has been inserted, the lungs should be ventilated 3at a rate of about 10 breaths per minute and chest compressions should continue without pausing during ventilation. Haemodynamic monitoring and treatment of reversible causes of the cardiac arrest are also important.
 
Atherosclerotic coronary artery disease
The management of a cardiac arrest secondary to an ACS event is similar to described in the ACS chapter of this book, with the aim of providing early revascularisation where appropriate.
 
Pericardiocentesis
When cardiac arrest is deemed secondary to a cardiac tamponade, the definitive treatment is pericardiocentesis. Needle pericardiocentesis can be performed in the apical, left parasternal, left sternocostal and subxiphoid approaches. In the emergency setting, when ultrasound guidance is unavailable, the subxiphoid or left sternocostal approaches are recommended. In a non-cardiac arrest scenario, lying the patient at 35–40 degrees brings the heart closer to the anterior chest wall, however, in a cardiac arrest situation, pericardiocentesis should be performed in the supine position. The pericardiocentesis/spinal needle should be inserted at 45 degrees to the chest wall, angled towards the patient's left shoulder. During advancement of the needle, it is important to maintain negative pressure on the syringe attached to the needle until fluid is aspirated into the syringe. Aspiration to dryness should be attempted, followed by insertion of a pericardial drain.
 
Complications
 
Pericardiocentesis
Complications associated with pericardiocentesis can occur both peri- and postprocedure. Awareness of structures surrounding the heart is important when performing pericardiocentesis. In addition to avoiding damage to the lungs and the liver, a number of key vessels lie between the myocardium and the thoracic cage that are prone to laceration. The left internal mammary artery lies approximately 1–2 cm from the border of the sternum which then forms the superior mesenteric artery at the level of the 6th intercostal space. The left anterior descending and the right coronary artery lie along the anterior pericardium. Puncture of the myocardium or coronaries can result in arrhythmia and a delayed onset haemopericardium. Patients may also often demonstrate a marked vasovagal response following periocardiocentesis.
FURTHER READING
  1. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–2964.
  1. Nolan J, Soar J, Hampshire S, et al. Advanced Life Support, 7th edn. London: Resuscitation Council (UK),  2016.
  1. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315.
  1. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569–2619.
 
Related topics of interest
  • Pericarditis, constriction and tamponade (p. 166)
  • Cardiac catheterisation and angiography (p. 31)
  • Channelopathies (p. 58)
  • Heart failure – chronic, long-term management (p. 80)
  • Imaging – echocardiography (p. 120)
  • Non-ST elevation – acute coronary syndromes (p. 153)
  • Percutaneous coronary intervention (p. 163)
  • ST segment elevation – myocardial infarction (p. 207)